Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
Alzheimer’s Disease International (ADI) and ITN Productions have co-produced a new documentary ‘Hope in the Age of Dementia'.
The following piece is from our third 'From Plan to Impact' report and written by ADI's Communications and Policy Manager, Annie Bliss, the main author of the report. In this piece, she writes about the impact of the COVID-19 pandemic on diagnostic, treatment, care and support services for people living with dementia.
A new report by ADI calls on world governments to ensure that dementia remains a priority during and after the COVID-19 pandemic.
Catherine Hall, Chief Executive of Alzheimers New Zealand, writes about how Alzheimers New Zealand has responded and adapted to COVID-19, both in the first weeks of lockdown and today.
Alzheimer’s Disease International (ADI) and partner Dementia Alliance International (DAI) join other civil society organisations in a statement to the World Health Organization (WHO).
In advance of the 73rd World Health Assembly, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
A new study in the Lancet Neurology has shown that blood phosphorylated tau 181 may be a promising biomarker for Alzheimer’s disease.
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.